Trump names physician Overton to lead FDA
Developed over time first seen 2 months ago
President Trump has nominated Dr Heidi Overton, currently his deputy assistant for domestic policy, to become the next commissioner of the US Food and Drug Administration. Overton, a physician known for her pro-life views, had been serving on the White House's Domestic Policy Council and would take charge of the agency responsible for regulating food, drugs, medical devices and other public health matters. The nomination continues Trump's pattern of placing figures aligned with Health Secretary Robert F. Kennedy Jr's agenda into senior health posts.
Announcing the nomination on Truth Social, Trump praised Overton as a "ROCKSTAR" in his administration, saying she had worked directly with Kennedy and Dr Mehmet Oz to advance what he called the "MOST TRANSFORMATIVE Health Agenda in History", and that she would continue "putting AMERICA FIRST" while building a "healthy America". No further details on a Senate confirmation timeline emerged following the announcement.
- Trump nominates Dr Heidi Overton as next FDA commissioner.
- Overton is a physician and current White House domestic policy adviser.
- Trump praised her work with Kennedy and Oz on health policy.
New here? Start with this
Trump has nominated Dr Heidi Overton to lead the Food and Drug Administration, the US federal agency responsible for regulating medicines, vaccines, medical devices, and food safety. The FDA commissioner oversees an agency that plays a central role in public health, deciding what drugs and treatments reach the American market and setting safety standards that affect millions of consumers.
Overton is a physician who has been serving in the White House as deputy assistant for domestic policy. She has previously expressed pro-life views, a factor likely to draw attention given the FDA's role in regulating reproductive health products, including medications used in abortion.
If confirmed, Overton would take charge of an agency whose decisions carry significant weight for the pharmaceutical industry, healthcare providers and patients across the United States, making the appointment one that is often closely scrutinised by lawmakers, industry groups and health advocates alike.
Both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
Supporters argue Dr Overton brings genuine medical credentials combined with policy experience from her time on the Domestic Policy Council, making her well-placed to run a complex regulatory agency. They see her as part of a broader effort to install leaders who will prioritise transparency, cut bureaucratic delay in drug and device approvals, and align FDA priorities with the administration's public health agenda, including scepticism of some existing regulatory orthodoxies. Her personal convictions, including pro-life views, are seen by supporters as a legitimate reflection of mainstream values that deserve representation in federal health leadership rather than a disqualifying factor.
The case against
Critics worry that appointing someone known chiefly for pro-life advocacy to lead the FDA risks politicising decisions that should rest on scientific and clinical evidence, particularly regarding reproductive health products such as mifepristone. They argue that the agency's credibility depends on commissioners being seen as independent from ideological commitments, and that a background primarily in White House domestic policy, rather than deep regulatory or public health administration experience, raises questions about readiness to run an agency overseeing food, drugs and medical devices. For sceptics, the concern is less about Overton personally and more about ensuring the FDA's scientific integrity remains insulated from political pressure.
More coverage
Celebrity Entertainment Government Politics World
Read the full article at the source →
Originally published by Fox News as “Trump to nominate Dr Heidi Overton as next FDA commissioner”.